NanoActive™Retinal – Bakuchiol
Nano-Encapsulated Retinal–Bakuchiol
Dual-Pathway Retinoid Renewal · Nano-Delivery Technology
INCI NAME — RETINAL, BAKUCHIOL
PuriPharm Co. Ltd. · Technical Marketing Presentation
02 · RETINOID CARE — THE NEXT CHAPTER
Retinoid Care Is Entering Its Next Stage
Retinoids remain the most evidence-supported active family for managing skin photoaging. The questions facing brands and formulators have moved beyond whether a formula contains a retinoid to four more fundamental issues: Can the active be converted efficiently? Can it remain stable? Can consumers sustain long-term use? Does the formula provide sufficient design freedom?
| Core question | Explanation |
|---|---|
| 01 Efficacy | Retinoids must be converted to retinoic acid to act; the conversion pathway determines the speed and intensity of activity. |
| 02 Stability | High activity comes with sensitivity to light and oxygen; active retention during shelf life and in-formula is essential. |
| 03 Tolerance | Irritation determines adherence, and adherence determines whether long-term benefits can be realized. |
| 04 Formulation | Dosage form, sensory profile and system compatibility define the space for product differentiation. |
The next-stage answer: advanced actives × complementary mechanisms × nano delivery.
03 · PRODUCT OVERVIEW
NanoActive™ Retinal-Bakuchiol
| Identity | Information |
|---|---|
| Product name | Nano-Encapsulated Retinal–Bakuchiol |
| INCI name | Retinal, Bakuchiol |
| Technology platform | NanoActive™ nano-encapsulation and delivery system |
| Application settings | Dual use across skin care and scalp care |
| 01 | Biology: Retinal is the direct precursor of retinoic acid; one oxidation step drives advanced retinoid biology. |
| 02 | Synergy: Bakuchiol supports retinol-like gene expression, antioxidant defense, inflammatory modulation, extracellular-matrix biology and skin homeostasis. |
| 03 | Delivery: NanoActive™ improves protection, dispersion, formulation suitability and delivery performance for sensitive actives. |
This is not a simple ingredient blend. It is a next-generation dual-pathway renewal platform integrating high-efficiency renewal, complementary mechanisms, nano delivery and both skin and scalp applications.
04 · 01 · BIOLOGY — RETINAL
Why Retinal: Closer to the Active EndpointRetinyl esters → Retinol → Retinal → Retinoic acid
| Metabolic node | Description |
|---|---|
| Retinyl esters | Storage form; hydrolyzed to retinol. |
| Retinol | Requires a rate-limiting oxidation step to form retinal. |
| Retinal | An advanced cosmetic retinoid that requires only one oxidation step to form retinoic acid. |
| Retinoic acid | The active retinoid endpoint; a drug active not permitted as a cosmetic ingredient. |
| Key advantage | Data and significance |
|---|---|
| Approximately 3× biological activity | Bypassing retinol’s first rate-limiting oxidation step gives retinal approximately three times the retinoid biological activity of retinol. |
| At least 11× faster conversion | Conversion of retinal to retinoic acid is estimated to be more than 11 times faster than the retinol pathway and occurs in both differentiated and undifferentiated keratinocytes. |
Retinal is the direct precursor of retinoic acid—an advanced retinoid positioned closer to the active endpoint.
Siegenthaler G, Saurat JH, Ponec M. Biochem J. 1990;268(2):371–378. | Brown A, et al. Dermatol Ther (Heidelb). 2023;13(10):2299–2317.
05 · 01 · BIOLOGY — ADVANCED RETINOID BIOLOGY
One Oxidation Step Directly Drives Classical Retinoid SignalingRetinal → one-step oxidation → retinoic acid → RAR/RXR nuclear receptors → target-gene transcription → visible epidermal and dermal renewal
| 01 | Retinal undergoes one oxidation step inside keratinocytes to form retinoic acid. |
| 02 | Retinoic acid binds nuclear RAR receptors and forms heterodimers with RXR. |
| 03 | RAR-RXR binds promoter regions and regulates target genes involved in skin biology. |
| 04 | The result is visible renewal across both the epidermis and dermis. |
| Level | Biological effects |
|---|---|
| Epidermis | Accelerated epidermal renewal; regulation of keratinocyte differentiation; increased epidermal thickness; upregulation of RA-activity markers such as CRABP-II; regulation of barrier- and hydration-related genes; improved desquamation, texture refinement and tone uniformity. |
| Dermis | Support for fibroblast function and extracellular-matrix remodeling; new collagen deposition; inhibition of UV-induced MMP-related matrix degradation; restoration of the elastic-fiber network; visible outcomes in wrinkles, texture, laxity and photoaging pigmentation. |
A complete retinoid-biology pathway drives systematic renewal from the epidermis to the dermis.
Saurat JH, et al. J Invest Dermatol. 1994;103(6):770–774. | Fisher GJ, et al. Nature. 1996;379(6563):335–339. | Xiao JH, et al. J Biol Chem. 1995;270(7):3001–3010.
06 · 01 · BIOLOGY — EPIDERMIS TO DERMIS
Retinal: From Epidermal Renewal to Dermal RemodelingEpidermis: renewal, differentiation, thickness and texture; Dermis: fibroblasts, collagen, elastic fibers, ECM and MMP management
| Evidence | Finding |
|---|---|
| Human study: epidermis and elasticity | After one year of 0.05% retinaldehyde, high-resolution ultrasound and rheological measurements showed significant increases in epidermal thickness and skin elasticity (p < 0.01), with a trend toward increased dermal thickness. |
| Ex vivo: repair of UVA damage | In a UVA-photodamaged human skin model, two weeks of 0.05% retinaldehyde restored elastic fibers and collagen to levels close to non-photodamaged skin. |
| Biological effects in human skin | Topical retinaldehyde induced typical retinoid effects, including epidermal thickening and CRABP-II expression, while maintaining good tolerance. |
Metabolic position → retinoid biology → epidermal renewal → ECM/collagen/elastin support → visible human outcomes: one complete evidence chain.
Diridollou S, et al. Dermatology. 1999;199(Suppl 1):37–41. | Boisnic S, et al. Dermatology. 1999;199(Suppl 1):43–48. | Saurat JH, et al. J Invest Dermatol. 1994;103(6):770–774.
07 · 01 · CLINICAL EVIDENCE — PHOTOAGING
Human Photoaging: Improvement Comparable to Retinoic Acid
| Study design | Details |
|---|---|
| Randomized controlled study | n=125; 18 weeks; optical profilometry; 0.05% retinaldehyde (n=40) versus 0.05% retinoic acid (n=40) versus vehicle (n=45). |
| Dimension | Result |
|---|---|
| Efficacy: comparable | Both actives significantly reduced wrinkles and skin roughness; no statistically significant efficacy difference was observed between retinaldehyde and retinoic acid. An open study (n=32, four months) also found clear reductions in surface roughness and coarse wrinkles. |
| Tolerance: better | Local irritation was more frequent with retinoic acid and affected adherence. Retinaldehyde caused fewer local adverse reactions and supported better long-term adherence. Comparable efficacy plus better tolerance forms retinal’s core value proposition. |
In photoaged human skin, 0.05% retinaldehyde delivered wrinkle and roughness improvements comparable to 0.05% retinoic acid while maintaining significantly better local tolerance.
Creidi P, et al. J Am Acad Dermatol. 1998;39(6):960–965. | Creidi P, Humbert P. Dermatology. 1999;199(Suppl 1):49–52. | Mukherjee S, et al. Clin Interv Aging. 2006;1(4):327–348.
08 · 01 · CLINICAL EVIDENCE — LONG-TERM
Elasticity, Skin Thickness and Long-Term Performance
One-Year Instrumental Study: 0.05% Retinaldehyde
n=21 in the retinaldehyde group versus n=19 in the emollient-control group; high-resolution ultrasound plus echorheometry; measurements at baseline and one year.
| 01 | Temporal epidermal thickness increased significantly versus control (p < 0.01). |
| 02 | Skin elasticity improved significantly versus control using suction rheology (p < 0.01). |
| 03 | Dermal thickness showed an increasing trend, while skin stiffness showed a decreasing trend. |
| 04 | Tolerance remained good throughout, supporting long-term daily use. |
Increase in Dermal Thickness with a Non-Ablative Laser Regimen
Randomized double-blind study (n=16); 0.05% retinaldehyde versus vehicle for three months.
Diridollou S, et al. Dermatology. 1999;199(Suppl 1):37–41. | Mordon data cited in Mukherjee S, et al. Clin Interv Aging. 2006;1(4):327–348.
09 · 01 · TOLERANCE PROFILE
High Activity Does Not Have to Mean High Irritation
In long-term clinical use, all three reaction rates were significantly lower with retinaldehyde; between-group analysis p < 0.0001.
| Setting | Finding |
|---|---|
| Maximized conditions | Retinol and retinaldehyde showed similarly low irritation potential, while retinoic acid was significantly more irritating (p < 0.05). Laser Doppler confirmed an irritant effect for RA but not for ROL/RAL (p = 0.001). |
| Long-term clinical conditions | Retinaldehyde demonstrated clear retinoid biological activity, while rates of erythema, scaling and burning/pruritus were significantly lower than with retinoic acid. |
| Product implication | Efficacy and user experience can coexist, supporting sustained use and repurchase in premium retinoid products. |
Fluhr JW, et al. Dermatology. 1999;199(Suppl 1):57–60. | Sachsenberg-Studer EM. Dermatology. 1999;199(Suppl 1):61–63.
10 · 02 · SYNERGY — BAKUCHIOL
Why Bakuchiol
Bakuchiol is a plant-derived molecule with retinol-like gene-expression effects and multi-pathway skin activity. It is more than a natural retinol alternative; it represents an independent multi-pathway biology.
| Feature | Description |
|---|---|
| Source and class | Derived from the seeds and leaves of Psoralea corylifolia; a meroterpene phenol. |
| Structure and function | Chemically dissimilar to retinoids but functionally analogous to retinol. |
| Mechanism | Does not directly engage the RAR receptor pathway, helping explain its gentler tolerance profile. |
| Use pattern | No reported photosensitivity; suitable for morning and evening use. |
Retinol-like gene expression, collagen and ECM support, antioxidant defense, inflammatory-signal modulation, skin homeostasis and barrier support, and pigment management
Antioxidant defense × inflammatory modulation × ECM support × homeostasis maintenance form a second renewal pathway beyond retinal.
Chaudhuri RK, Bojanowski K. Int J Cosmet Sci. 2014;36(3):221–230.
11 · 02 · SYNERGY — GENE EXPRESSION & COLLAGEN
Bakuchiol: Retinol-Like Gene Expression × ECM Support
| Evidence dimension | Finding |
|---|---|
| Collagen expression | Human dermal fibroblast model; ELISA; untreated control set at 100%; 10 μg/mL. Bakuchiol exceeded retinol for Collagen I and IV expression and was comparable for Collagen III. |
| Gene-expression profile | DNA microarray analysis in a full-thickness reconstructed skin model showed highly similar overall regulation by bakuchiol and retinol, including upregulation of COL1A2, COL4A6, COL9A2, COL17A1, HAS3 and hydration-related AQP3. |
| Non-classical RA pathway | No effect on RA receptor genes such as RARB and RARG, suggesting action through non-classical retinoic-acid signaling and supporting a gentler irritation profile. |
| 12-week human study | 0.5% bakuchiol significantly improved fine lines and wrinkles, pigmentation, elasticity, firmness and overall photodamage without the adverse effects commonly associated with retinol therapy. |
Chaudhuri RK, Bojanowski K. Int J Cosmet Sci. 2014;36(3):221–230. | Brown A, et al. Dermatol Ther (Heidelb). 2023;13(10):2299–2317.
12 · 02 · BAKUCHIOL — HUMAN EVIDENCE
Comparable Efficacy to 0.5% Retinol with Better Tolerance
Study design: prospective, randomized, double-blind study; n=44; 12 weeks; 0.5% bakuchiol twice daily versus 0.5% retinol once daily; high-resolution facial imaging plus blinded dermatologist grading.
| Tolerance difference | Description |
|---|---|
| Retinol | More facial scaling and stinging were reported. |
| Bakuchiol | Suitable for morning and evening use, with no reported photosensitivity; offers wider design space for sensitive skin and higher-frequency use. |
Head-to-head human evidence shows that bakuchiol was comparable to 0.5% retinol for both wrinkles and pigmentation, with better tolerance.
Dhaliwal S, et al. Br J Dermatol. 2019;180(2):289–296. | Draelos ZD, et al. J Drugs Dermatol. 2020;19(12):1181–1183.
13 · 03 · COMPLEMENTARY BIOLOGY
Two Actives, Two Complementary Biological Systems
| Dimension | Retinal | Bakuchiol | Complementary value |
|---|---|---|---|
| Core pathway | Direct precursor of retinoic acid → classical RAR retinoid signaling | Retinol-like transcriptional response via a non-classical RA pathway | Dual-pathway coverage without full overlap |
| Epidermal action | Epidermal renewal, keratinocyte differentiation and epidermal thickness | Barrier and homeostasis support; enhancement of differentiation-related genes | Renewal plus homeostasis |
| ECM/collagen | Fibroblast function, new collagen deposition and MMP inhibition | Collagen I/III/IV expression and ECM support | Synthesis promotion × degradation management |
| Oxidation/inflammation | Management of photoaging-related matrix degradation | ROS defense and inflammatory-signal modulation | A protective environment for high-efficiency activity |
| Pigment/blemish-prone skin | Depigmenting activity, keratinization renewal and C. acnes inhibition | Pigmentation improvement and blemish-prone skin support | Multi-target clarity and tone management |
| Tolerance | Significantly better than retinoic acid | Better than 0.5% retinol in a head-to-head study | Long-term-use friendliness for premium products |
One pathway is a high-efficiency engine operating through classical RAR signaling; the other is a multi-pathway support system for homeostasis—Retinal × Bakuchiol complementary biology.
14 · 03 · DUAL-PATHWAY RENEWAL
Dual-Pathway Renewal: A More Complete Renewal LogicClassical RAR signaling from retinal plus multi-pathway homeostasis support from bakuchiol
| Retinal pathway | Bakuchiol pathway |
|---|---|
| One-step oxidation to retinoic acid | Plant-derived meroterpene phenol |
| RAR-RXR heterodimer and target-gene transcription | Retinol-like transcriptional response plus antioxidant and inflammatory modulation; non-classical RA pathway, NF-κB and ROS defense |
| Epidermal renewal, keratinocyte differentiation, ECM remodeling, collagen homeostasis and MMP management | Skin homeostasis, barrier support, ECM support, photoaging defense and pigment management |
Dual-pathway retinoid renewal: epidermal renewal · ECM support · oxidative defense · homeostasis maintenance.
15 · 03 · RETINAL + BAKUCHIOL — COMBINED HUMAN EVIDENCE
Combined-System Human Study: Multidimensional Signals in 28 Days
Study design: open-label proof of concept; n=32 women, 65.6% with sensitive skin; once nightly for 28 days; a complex containing 0.1% liposomal retinal plus bakuchiol, with Vigna aconitifolia extract, niacinamide and melatonin.
| 01 | 100% of subjects showed a reduction in crow’s-feet count; all 32 of 32 participants improved. |
| 02 | Good tolerance: no significant changes in erythema or burning/stinging; no participant, including those with sensitive skin, needed to alter the once-daily regimen. |
| 03 | Methods: Cutometer® for firmness R0 and elasticity R2, Primos®-CR for wrinkles and VISIA®-CR for tone; D0–D28 change from baseline; *p<0.05, ***p<0.001. |
Note: These data describe the complete active system containing retinal plus bakuchiol and do not isolate the individual contribution of either ingredient.
Brown A, et al. Dermatol Ther (Heidelb). 2023;13(10):2299–2317.
16 · 03 · FROM EFFICACY TO MECHANISM
From Human Efficacy to Molecular Mechanism
| 01 | Enhanced gene expression: In a full-thickness reconstructed human skin model, adding bakuchiol to 0.1% retinal further enhanced retinal’s regulation of keratinocyte-differentiation genes CASP14, KRT14 and TP63 and barrier genes FLG, CDSN and CLDN1. Several changes exceeded the 0.05% retinoic-acid control. |
| 02 | No increase in irritation potential: In a reconstructed human epidermis model, ET50 remained >24 hours for both 0.1% retinal alone and retinal + bakuchiol + Vigna aconitifolia extract, maintaining gentleness while improving performance. |
| 03 | Mechanistic interpretation: Bakuchiol upregulated CRABP-II and genes related to retinol metabolism, supporting efficient RA signaling and providing a complementary mechanistic explanation for combined-system efficacy. |
Ex Vivo UV-Photodamaged Skin Model: Combined System
| Marker | Change |
|---|---|
| CRABP-II expression | +68% |
| Hyaluronic acid | +71% versus UV-exposed skin |
| Procollagen I | +33% |
| Degraded collagen | −46% by CHP staining |
| MMP-1 expression | −36% |
| Total collagen | +16%, fully preventing UV-induced loss |
Scientific boundary: the evidence demonstrates multidimensional efficacy and complementary mechanisms for the combined system; it does not prove strict pharmacological synergy between the two ingredients.
Brown A, et al. Dermatol Ther (Heidelb). 2023;13(10):2299–2317.
17 · 04 · DELIVERY — THE FORMULATION CHALLENGE
Why Nano Delivery Is Needed
| Retinal: high activity, high sensitivity | Bakuchiol: the dispersion challenge of a lipophilic molecule |
|---|---|
| Oxidation-sensitive aldehyde structure | Lipophilic and naturally incompatible with high-water systems |
| Light-sensitive, with activity loss under illumination | Application and dispersion challenges in high-water systems |
| Storage-stability challenges | Formula uniformity requires technical support |
| Free active is vulnerable to the formulation environment | System compatibility requires optimization |
High activity does not automatically equal high performance. An active must be protected, dispersed and delivered before efficacy can be realized in a formula. NanoActive™ encapsulation is designed for sensitive actives.
18 · 04 · DELIVERY — NANOACTIVE™ TECHNOLOGY
Nano-Encapsulation Converts High Activity into High PerformanceNano-carriers encapsulate retinal and bakuchiol across protection, dispersion, delivery and formulation performance
| 01 | Protection: Isolates and protects sensitive actives, reducing direct exposure to light, oxygen and the formulation environment. |
| 02 | Dispersion: Improves the dispersion and uniformity of lipophilic actives in high-water systems and optimizes compatibility. |
| 03 | Delivery: Supports even delivery and distribution of actives on the skin. |
| 04 | Performance: Improves development flexibility across serums, emulsions, gels and other modern formats—converting high activity into high formulation performance. |
19 · 04 · FREE ACTIVE vs NANO-ENCAPSULATED
Free Active vs Nano-Encapsulated
| Free active | NanoActive™ encapsulation system |
|---|---|
| Light/oxygen/formulation environment: direct exposure to degradation factors | Active encapsulation: retinal and bakuchiol loaded into nano-carriers |
| Activity loss during storage and shelf life | Protection from light, oxygen and the formulation environment |
| Dispersion challenge and limited uniformity in high-water systems | Stable and uniform distribution in high-water systems |
| Restricted delivery, reduced performance and narrower dosage-form choice | Uniform delivery and greater design freedom across serums, emulsions, gels and other modern formats |
Specific technical parameters such as particle size, encapsulation efficiency, release profile and stability are subject to the PuriPharm product technical documents (TDS/COA).
20 · 05 · APPLICATION — SKIN PERFORMANCE
Wrinkles · Firmness · Elasticity · Renewal
| 01 | Wrinkles and photoaging: RAR-driven epidermal renewal and dermal remodeling; a retinal + bakuchiol system reduced wrinkle count by 43.2% in 28 days (p<0.001); retinaldehyde produced wrinkle and roughness improvement comparable to retinoic acid in an n=125 randomized trial. |
| 02 | Firmness and elasticity: Support for Collagen I/III, elastin, ECM and MMP management; after 28 days, elasticity increased 13.9% (p<0.001) and firmness increased 5.6% (p<0.05); one year of 0.05% retinaldehyde significantly improved skin elasticity (p<0.01). |
| 03 | Epidermal renewal: Regulation of keratinocyte differentiation and renewal, increased epidermal thickness (p<0.01), and improved texture and radiance—the mechanistic basis for night renewal and Skin Longevity products. |
| 04 | Tone improvement: Retinal depigmenting activity and epidermal renewal plus bakuchiol-associated pigment improvement in 59% of subjects; tone uniformity increased 7.0% after 28 days (p<0.05). |
Brown A, et al. Dermatol Ther (Heidelb). 2023;13(10):2299–2317. | Diridollou S, et al. Dermatology. 1999;199(Suppl 1):37–41. | Sorg O, et al. Dermatology. 2013;227(3):231–237. | Dhaliwal S, et al. Br J Dermatol. 2019;180(2):289–296.
21 · 05 · APPLICATION — ANTIOXIDANT · BLEMISH-PRONE SKIN
Antioxidant Defense and Blemish-Prone Skin Microenvironment ManagementUV/pollution → ROS → oxidative stress → inflammatory signaling → increased MMP → collagen degradation; bakuchiol supports ROS defense, inflammatory modulation and MMP management
A Distinct Antibacterial Dimension of Retinal
| 01 | In vivo: daily 0.05% retinaldehyde reduced median viable C. acnes density by 10² log/cm² after two weeks; vehicle had no effect. |
| 02 | Comedolytic and keratinization-renewal activity was observed in an animal model. |
| 03 | Bakuchiol antioxidant and inflammatory-modulating activity supports blemish-prone skin care. |
| 04 | Cosmetic language: clarity, balance, keratin renewal, blemish-prone skin care and microenvironment management. |
Pechère M, et al. Dermatology. 1999;199(Suppl 1):29–31. | Fort-Lacoste L, et al. Dermatology. 1999;199(Suppl 1):33–35. | Chaudhuri RK, Bojanowski K. Int J Cosmet Sci. 2014;36(3):221–230.
22 · 06 · SKIN & SCALP LONGEVITY
From Skin Longevity to Scalp Longevity
The scalp is an extension of facial skin. The same biology that drives facial renewal—epidermal turnover, barrier homeostasis, oxidative-stress management and ECM support—also applies to the scalp and follicular microenvironment.
Skin Longevity → Scalp Longevity → Follicular Microenvironment
| Setting | Core biology |
|---|---|
| Facial skin | Renewal, ECM, tone and homeostasis |
| Scalp | Keratinization renewal, barrier, ROS and inflammatory microenvironment |
| Follicular microenvironment | Epithelial homeostasis and perifollicular ECM |
| 01 | Scalp aging involves declining barrier function, accumulated oxidative stress and changes in the follicular microenvironment, sharing a mechanistic framework with facial photoaging. |
| 02 | The dual-pathway logic of retinoid biology and antioxidant support naturally extends to scalp-renewal applications. |
| 03 | The NanoActive™ delivery system supports dispersion and delivery in lightweight scalp-serum formats. |
Positioning: Scalp Longevity Active System | Scalp Longevity Serum | Advanced Scalp Renewal | Skin & Scalp Longevity
23 · 06 · SCALP & FOLLICLE BIOLOGY
Scalp Renewal and Follicular Microenvironment SupportScalp epidermis, dermal/follicular zone and follicular microenvironment
| Level | Support direction |
|---|---|
| Scalp epidermis | Keratinization renewal, scalp barrier and homeostasis |
| Dermal/follicular zone | Follicular epithelium, perifollicular ECM and sebaceous glands |
| Follicular microenvironment | ROS management, inflammatory signaling and environmental stress |
| 01 | Retinoid biology and the follicle: Retinoic-acid synthesis is localized to specific regions of the follicle and sebaceous gland, including the stem-cell microenvironment. Precisely regulated RA levels are essential to follicular epithelial homeostasis. |
| 02 | Oxidative stress and scalp aging: Oxidative stress is an important driver of scalp and hair aging. Bakuchiol’s antioxidant and inflammatory-modulating properties provide protective support for the perifollicular microenvironment. |
| 03 | Product positioning: Focuses on the scalp-care environment and biological support—scalp renewal, barrier maintenance and follicular microenvironment management—without drug-like hair-growth or anti-hair-loss claims. |
Everts HB. Biochim Biophys Acta. 2012;1821(1):222–229. | Trüeb RM. Int J Trichology. 2009;1(1):6–14. | Trüeb RM. Int J Cosmet Sci. 2015;37(Suppl 2):25–30.
24 · 07 · APPLICATION MAP
Multi-Setting Applications
| Face | Eye | Scalp & Hair |
|---|---|---|
| Advanced anti-aging serumsNight-renewal serumsLine-smoothing serumsFirming creamsSkin Longevity productsPhotoaging careTone-radiance careBlemish-prone skin care | Eye serumsLine-smoothing eye creamsCrow’s-feet managementIn the combined-system study, 100% of subjects showed fewer crow’s feet after 28 days | Scalp serumsAnti-aging scalp serumsScalp Longevity SerumHair Vitality SerumNight scalp careFollicular microenvironment care |
Premium concepts: Retinoid Cycling | Skin Longevity | Scalp Longevity | Healthy Aging | Preventive Aging | Night Renewal
25 · THE PLATFORM
A Next-Generation Dual-Pathway Retinoid Renewal PlatformAdvanced retinal biology + complementary multi-pathway bakuchiol activity + NanoActive™ nano delivery
| Platform value | Description |
|---|---|
| Performance | One oxidation step to RAR signaling, supported by a complete human-efficacy evidence chain. |
| Complementary biology | Retinol-like gene expression × antioxidant defense × homeostasis support. |
| Delivery | Protection, dispersion and delivery convert high activity into high formulation performance. |
| Skin + scalp applications | A platform spanning both Skin Longevity and Scalp Longevity. |
NanoActive™ Retinal-Bakuchiol: Retinoid performance, redefined.
PuriActives® and NanoActive™ are trademarks of PuriPharm Co., Ltd. This material is intended solely for technical communication concerning cosmetic ingredients.
26 · SCIENTIFIC REFERENCES
Scientific References
| 01 | Siegenthaler G, Saurat JH, Ponec M. Retinol and retinal metabolism. Relationship to the state of differentiation of cultured human keratinocytes. Biochem J. 1990;268(2):371–378. |
| 02 | Saurat JH, et al. Topical retinaldehyde on human skin: biologic effects and tolerance. J Invest Dermatol. 1994;103(6):770–774. |
| 03 | Creidi P, et al. Profilometric evaluation of photodamage after topical retinaldehyde and retinoic acid treatment. J Am Acad Dermatol. 1998;39(6):960–965. |
| 04 | Creidi P, Humbert P. Clinical use of topical retinaldehyde on photoaged skin. Dermatology. 1999;199(Suppl 1):49–52. |
| 05 | Diridollou S, et al. Efficacy of topical 0.05% retinaldehyde in skin aging by ultrasound and rheological techniques. Dermatology. 1999;199(Suppl 1):37–41. |
| 06 | Boisnic S, et al. Repair of UVA-induced elastic fiber and collagen damage by 0.05% retinaldehyde cream in an ex vivo human skin model. Dermatology. 1999;199(Suppl 1):43–48. |
| 07 | Pechère M, et al. Antibacterial activity of retinaldehyde against Propionibacterium acnes. Dermatology. 1999;199(Suppl 1):29–31. |
| 08 | Fort-Lacoste L, et al. Comedolytic effect of topical retinaldehyde in the rhino mouse model. Dermatology. 1999;199(Suppl 1):33–35. |
| 09 | Fluhr JW, et al. Tolerance profile of retinol, retinaldehyde and retinoic acid under maximized and long-term clinical conditions. Dermatology. 1999;199(Suppl 1):57–60. |
| 10 | Sachsenberg-Studer EM. Tolerance of topical retinaldehyde in humans. Dermatology. 1999;199(Suppl 1):61–63. |
| 11 | Mukherjee S, et al. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clin Interv Aging. 2006;1(4):327–348. |
| 12 | Sorg O, et al. The potential depigmenting activity of retinaldehyde. Dermatology. 2013;227(3):231–237. |
| 13 | Kwon HS, et al. Efficacy and safety of retinaldehyde 0.1% and 0.05% creams used to treat photoaged skin: a randomized double-blind controlled trial. J Cosmet Dermatol. 2018;17(3):471–476. |
| 14 | Chaudhuri RK, Bojanowski K. Bakuchiol: a retinol-like functional compound revealed by gene expression profiling and clinically proven to have anti-aging effects. Int J Cosmet Sci. 2014;36(3):221–230. |
| 15 | Dhaliwal S, et al. Prospective, randomized, double-blind assessment of topical bakuchiol and retinol for facial photoageing. Br J Dermatol. 2019;180(2):289–296. |
| 16 | Brown A, et al. Natural retinol analogs potentiate the effects of retinal on aged and photodamaged skin: results from in vitro to clinical studies. Dermatol Ther (Heidelb). 2023;13(10):2299–2317. |
| 17 | Draelos ZD, et al. Clinical evaluation of a nature-based bakuchiol anti-aging moisturizer for sensitive skin. J Drugs Dermatol. 2020;19(12):1181–1183. |
| 18 | Fisher GJ, et al. Molecular basis of sun-induced premature skin ageing and retinoid antagonism. Nature. 1996;379(6563):335–339. |
| 19 | Everts HB. Endogenous retinoids in the hair follicle and sebaceous gland. Biochim Biophys Acta. 2012;1821(1):222–229. |
| 20 | Trüeb RM. Oxidative stress in ageing of hair. Int J Trichology. 2009;1(1):6–14. |